Although tumour necrosis factor-alpha inhibitor (TNFi) therapy has proven efficacy in the management of psoriatic arthritis (PsA), relatively little is known about predictors of TNFi persistence. Such knowledge would assist the application of stratified medicine. Objectives: To determine baseline clinical characteristics associated with TNFi persistence in patients receiving their first-line agent, and to compare TNFi persistence in first versus second-line users. Methods: A retrospective cohort study was performed of all patients with PsA attending a single-centre between [2003][2004][2005][2006][2007][2008][2009][2010][2011][2012][2013][2014][2015][2016]. Demographic, clinical and laboratory characteristics were compared with TNFi persistence, using KaplanMeier survival analysis and multivariable Cox proportional hazards models. Results: A total of 188 PsA cases had used TNFi therapy as first-line over a period spanning 7,620 person months: 46% male; mean age at TNFi initiation 47.27 (SD 11.36) years; median disease duration at initiation 11 (IQR 7,16) Figure  1 ], with no significant contribution from other co-variables.
Background: Axial involvement in early psoriatic arthritis (ePsA) patients (pts) is often asymptomatic, poorly diagnosed and has not been studied properly. Magnetic resonance imaging (MRI) of sacroiliac joints (SIJs) helps to better define spinal involvement in ePsA. Objectives: to study the prevalence of axial involvement in peripheral ePsA pts. Methods: 89 pts (M/F-42 /47) with peripheral ePsA according to CASPAR criteria were included; mean age 36.5±10.9 yrs, disease duration 12.1±10.1 mo., disease activity index (DAS) 5.2±2.8, C-RP 16.1 [6.6; 31.0] mg/l, ESR 22.5±19.2 mm/h. All patients were evaluated for the presence of inflammatory back pain (IBP) by ASAS criteria. In pts having IBP disease activity was also measured according to BASDAI. The examination included X-ray of sacroiliac joints (SIJs) (pelvic radiograph), HLA B27 antigen, MRI of SIJs was performed in 79 pts, both with and without IBP, on Signa Ovation 0,35T. Bone marrow edema on MRI (STIR), considered as active MRI sacroiliitis (MRI-SI), was evaluated by an independent reader. Radiographic sacroiliitis (R-SI) was defined when 2 grade changes in at least one SIJ appear, and included definite radiographic SI (dR-SI) and "non-definite" radiographic SI (ndR-SI). dR-SI was determined according to New York criteria (unilateral grade≥3 or bilateral grade≥2). 2 grade changes in only one SIJ were qualified as ndR-SI. Results: IBP was found in 58 out of 89 (65.1%) pts, 35 (60.3%) of them had short-term (episodic) IBP, and 23 (39.7%) pts had long-term IBP. MRI-SI was observed in 28 out of 79 (35.4%) pts. R-SI was determined in 42 out of 89 (47.2%) pts, while dR-SI was found in 27 out of 89 (30.3%) pts, the remaining 15 (16.9%) pts had ndR-SI. 34 (38. 2%) pts were HLA B27 positive. In pts having IBP disease activity according to BASDAI was 4.5±1.6. Correlation has been detected between MRI-SI and IBP: among the group of pts having MRI-SI IBP was observed in 92.9% cases while out of the group of patients without MRI-SI in 54.9% cases (p=0.0002). An association was found between MRI-SI and long-term IBP (p=0.003) as well as between MRI-SI and short-term IBP (p=0.006). Moderate correlation has been detected between the presence of dR-SI and IBP (p=0.038). It's worth noting that among the 26 pts having dR-SI, 5 (19.2%) pts never had IBP before. And among the 15 pts having ndR-SI, 6 (40.0%) pts never had IBP before. No association was found between the presence of MRI-SI/R-SI/dR-SI and HLA B27 status. Conclusions: in the Russian cohort of early peripheral psoriatic arthritis pts, careful examination quite often revealed high prevalence of axial involvement: 65% of pts had IBP (moreover, more than half of them (60%) had short-term IBP), 35% of pts had MRI-SI, half of the pts had R-SI, one third of the pts had definite R-SI. A significant number of patients (40%) developed 2 grade changes in one SIJ without previous IBP. An association was found between IBP and SI revealed by any of the visualization methods used. No association has been detected between the presence of MRI-SI or R-SI and HLA B27 status. These data indicate that in peripheral ePsA pts axial involvement is often asymptomatic and is poorly diagnosed. Careful identification of IBP together with MRI of SIJs will help to better define spinal involvement. Background: Treat-to-target (T2T) strategy has benefit in early psoriatic arthritis (EPsA) treatment. Its influence on radiographic progression has limited data. Objectives: to investigate radiographic outcomes and minimal disease activity (MDA) after 1-year of T2T strategy in patients with EPsA. Methods: 40 (M-18/F-22) DMARD-naïve pts with active EPsA, according to the CASPAR criteria, mean age 38.4±11.1 yrs., PsA duration 11.9±10.6 months, psoriasis duration 73.8±84.6 months, median DAS 3. 8 [3.2; 4.7] from the open-label REMARCA study were included. At baseline all pts were treated by Methotrexate (MTX) subcutaneous (s/c) 20-25 mg/week. Pts that still had medium or high activity after 3-6 months were treated by combination therapy MTX+ biologic therapy (BT) -anti-TNF or Ustekinumab (n=21). By the end of the study, 19 pts were treated by MTX-monotherapy. At baseline and after 1-yr. of treatment PsA activity index and digital radiographs of hands and feet were performed. All images were scored according to Sharp/van der Heijde (Sh. In 29 out of 40 pts (72.5%) there was no X-ray progression considering both erosion and joint space narrowing. 13 of them (45%) were treated by MTX and 16 pts (55%) by MTX+BT. Negative X-ray progression was found in 11 out of 40 pts (27.5%): 6 of them (54.5%) were treated by MTX and 5 pts (45.5%) by MTX+BT. 
Conclusions:
In the Russian cohort of active EPsA pts erosion was found in more than half of cases. Active EPsA pts treated according to T2T strategy during 1 year in 72.5% did not show any radiographic progression, only a quarter of pts (27.5%) had negative X-ray progression by the end of the study, regardless of the type of therapy. The pts who achieved MDA had less erosive progression. Antihypertensive therapy received all pts with AH. Methotrexate (MT) therapy was started in all pts with an escalation of the dose up to 25 mg/week subcutaneously. In case of no remission 3 months later, MT was added with biologic therapy: Adalimumab, Certolizumabpegol, Ustekinumab. 23 subjects were assessed after 18 months of therapy. Results: After 18 months of therapy DAS and CRP level decreased significantly, p=0.001. DAS remission was achieved in 82.6% of pts. The incidence rate of AH (39% vs 39%), obesity (30% vs 21%), smokers (39% vs 39%), menopausal status (17% vs 17%), atherosclerotic plaques (39% vs 39%), did not change significantly. High-density lipoproteins increased significantly from 1.2 [1.1; 1.6] to 1.5 [1.2; 2.1]mmol/l, p=0.03. We didn't find significant differences between baseline and after treatment levels of total cholesterol/low-density lipoproteins level: from 5.2 [4.6; 6.0] to 5.2 [4.5; 5.9] (p=0.47) mmol/l and from 3.4 [2.8; 3.8] to 3.3 [2.6; 3.6] (p=0.60) mmol/l. HRVs parameters didn't change significant (table 1). 
